DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Rilvegostomig
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Docetaxel

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]